Comparison of Montelukast and Azelastine in Treatment of Moderate to Severe Allergic Rhinitis

Last updated: September 23, 2020
Sponsor: Shiraz University of Medical Sciences
Overall Status: Active - Recruiting

Phase

N/A

Condition

Allergy (Pediatric)

Allergies & Asthma

Allergy

Treatment

N/A

Clinical Study ID

NCT04561687
98-01-49-21547
  • Ages 6-50
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Comparison of Montelukast and Azelastine In treatment of Allergic Rhinitis Allergic intent is one of the most common diseases of the respiratory system that has a devastating effect on the quality of life. The importance of studying this disease can be seen from the high prevalence of this diseas. In addition to the high prevalence, due to the reducing effect of this disease on the economy and academic performance of patients, a great burden is imposed by this disease on the country's health care system.Also finding the best treatment of allergic can help to control of Asthma if exists concurrently.

Inflammation of the nasal mucosa following the release of IgE can be shown as symptoms of runny nose, sneezing, nasal congestion.Many studies have been done in the field of allergic rhinitis to increase the cost-effectiveness of treatment of this complication. Among the treatments for this disease is the use of antihistamine nasal sprays such as Azelastine. Combination therapies such as combining Mometason furoate or fluticasone with Azelastine or Montelukast can also be mentioned. However, there is still a long way to go to find the best drug combination to reduce the economic and human costs to the global health system. Due to the high prevalence of allergic diseases such as allergic rhinitis, finding the best treatment or management of such diseases plays an important role in improving the quality of life and reducing the economic burden on society.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 6-50years

  • Moderate to severe allergic rhinitis

Exclusion

Exclusion Criteria:

  • Under any treatment

  • Drug sensitivity

Study Design

Total Participants: 66
Study Start date:
January 16, 2020
Estimated Completion Date:
December 15, 2021

Connect with a study center

  • Shiraz University of Medical Science

    Shiraz,
    Iran, Islamic Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.